Arizona State Retirement System Sells 22,221 Shares of Bristol Myers Squibb Company $BMY

Arizona State Retirement System decreased its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 3.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 572,362 shares of the biopharmaceutical company’s stock after selling 22,221 shares during the quarter. Arizona State Retirement System’s holdings in Bristol Myers Squibb were worth $30,873,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. Darwin Wealth Management LLC bought a new position in Bristol Myers Squibb in the 2nd quarter worth approximately $25,000. Harbor Capital Advisors Inc. raised its position in Bristol Myers Squibb by 107.2% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 313 shares during the last quarter. KERR FINANCIAL PLANNING Corp bought a new position in Bristol Myers Squibb in the 3rd quarter worth approximately $35,000. JPL Wealth Management LLC bought a new position in Bristol Myers Squibb in the 3rd quarter worth approximately $36,000. Finally, Beacon Financial Strategies CORP bought a new position in Bristol Myers Squibb in the 4th quarter worth approximately $38,000. Institutional investors own 76.41% of the company’s stock.

Insider Activity

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the sale, the executive vice president directly owned 159,248 shares in the company, valued at $9,820,824.16. This represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.05% of the stock is owned by company insiders.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Barclays upgraded BMY to a Buy, which can support the stock by drawing investor interest and providing a catalyst for further upside. Read More.
• Positive Sentiment: Atrium Therapeutics announced it earned a $15 million development milestone payment from Bristol Myers Squibb under a global cardiovascular collaboration — a signal that a partnered program has hit a development milestone, de‑risking part of BMY’s external pipeline (though it represents a cash outflow). Read More.
• Positive Sentiment: Positive coverage pieces highlighting BMY as a momentum/long‑term holding can attract buy‑and‑hold investors and support multiple expansion. Read More.
• Neutral Sentiment: BMY is a counterparty on a corporate PPA: a new solar project will supply power through previously signed PPAs that include Bristol Myers Squibb — a modest ESG/operational positive but unlikely to move the stock materially. Read More.
• Neutral Sentiment: Industry market reports (vulvar cancer, Sjögren’s syndrome) mention Bristol Myers Squibb among major players — useful context on addressable markets but not an immediate stock driver. Read More. | Read More.
• Neutral Sentiment: Bristol Myers Squibb is expected to report quarterly earnings this week — the timing itself is a catalyst but the direction depends on results and guidance. Read More.
• Negative Sentiment: Analyst previews from Yahoo/Zacks flag that BMY currently lacks the “right combination” of factors (revenue mix and margin tailwinds) that typically produce an earnings beat; consensus calls for a decline in EPS, heightening the risk of a negative market reaction if results disappoint. Read More.
• Negative Sentiment: Bernstein maintained a Hold on BMY, a cautious stance that can cap upside from upgrades and keeps some investors sidelined. Read More.

Analyst Ratings Changes

BMY has been the subject of several research analyst reports. Bank of America dropped their price objective on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating for the company in a research report on Thursday, April 9th. Barclays began coverage on shares of Bristol Myers Squibb in a research note on Thursday, February 19th. They set an “overweight” rating and a $75.00 price target for the company. Wells Fargo & Company reissued an “outperform” rating and set a $60.00 price target (up from $55.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Weiss Ratings reissued a “hold (c)” rating on shares of Bristol Myers Squibb in a research note on Monday, March 23rd. Finally, Royal Bank Of Canada began coverage on shares of Bristol Myers Squibb in a research note on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 price target for the company. Eight investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $61.31.

Bristol Myers Squibb Stock Performance

Shares of BMY stock opened at $59.02 on Friday. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14. The stock has a market cap of $120.50 billion, a PE ratio of 17.11, a price-to-earnings-growth ratio of 0.17 and a beta of 0.27. The stock has a 50-day moving average of $59.72 and a 200-day moving average of $53.99. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). The company had revenue of $12.50 billion during the quarter, compared to the consensus estimate of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The business’s revenue was up 1.3% compared to the same quarter last year. During the same period last year, the company earned $1.67 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, sell-side analysts expect that Bristol Myers Squibb Company will post 6.28 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 4.3%. The ex-dividend date is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio is 73.04%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.